Alector (ALEC): Analyst Targets Center on $3.60 With +99% Upside Potential
Key Takeaways
- The $3.60 central target is the arithmetic mean of four verified analyst price targets: $5.00 (H.C. Wainwright), $6.00 (BTIG), $2.00 (Morgan Stanley), and $1.50 (Mizuho).
- Based on Alector's October 2, 2026 close of $1.81, reaching $3.60 would require roughly a 99% advance — a very large move.
- The analyst range is extremely wide, from $1.50 to $6.00, reflecting deep disagreement after a late-2025 clinical setback and an October 2026 licensing deal.
- The strongest support is a new Genentech (Roche) agreement on the AL050 Parkinson's program, worth up to about $1.27 billion including an upfront payment.
- The biggest risks are ongoing clinical-stage losses, cash burn, and the history of trial-driven sell-offs.
Analyst Price Targets and Consensus View
Alector, Inc. (ALEC) is a clinical-stage immuno-neurology biotechnology company developing therapies for neurodegeneration, including Alzheimer's and Parkinson's disease. Its sell-side coverage is thin and unusually divergent, which is why the headline target should be read as a calculated midpoint rather than a forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Four verifiable, current price targets were reviewed: H.C. Wainwright's Andrew Fein reiterated a Buy with a $5.00 target in December 2025, after cutting it from $10.00 following the INFRONT-3 data miss; BTIG set a Buy with a $6.00 target in early 2026; Mizuho's Graig Suvannavejh downgraded the stock to Hold with a $1.50 target in November 2025; and Morgan Stanley, which maintains an Underweight (Sell) rating, carries a $2.00 target. The arithmetic mean is $3.625, rounded to $3.60. The low-to-high spread — roughly $1.50 to $6.00, a fourfold gap — is itself a signal of how sharply opinions differ.
Several other firms, including William Blair, TD Cowen, and Cantor Fitzgerald, rate the stock but do not publish explicit numeric targets, which limits the sample. Published "consensus" figures elsewhere also vary, roughly between $2 and $3, because providers count different analysts. Bulls cite diversified pipeline optionality across AL137, AL050, and the siRNA programs; bears emphasize the failed AL001 readout and the company's ongoing losses.
Current Market Position and Path Toward the Target
Alector shares last closed at $1.81 on October 2, 2026, near the lower end of a 52-week range of $1.09 to $3.40. In early October 2026 the stock rallied sharply after the company announced an exclusive global licensing agreement with Genentech, a Roche unit, for the AL050 program — an engineered GCase enzyme replacement therapy for Parkinson's disease tied to GCase deficiency. The deal includes a $100 million upfront payment and up to about $1.17 billion in milestone payments, plus royalties.
From the $1.81 close, the $3.60 central target implies upside of roughly 99%, a very large move for a company with a market capitalization of about $200 million. A path to that level would most plausibly rest on sustained execution of the now-partnered AL050 program and progress on the broader pipeline, rather than on current financials, which remain minimal: third-quarter 2025 collaboration revenue was about $3.26 million against a GAAP net loss of roughly $34.7 million.
What Could Support a Move Toward the Target
- The Genentech/Roche partnership validates the AL050 program, brings a substantial upfront payment, and shifts development and commercialization costs to a well-capitalized partner.
- A strategic collaboration with GSK covers progranulin-elevating antibodies, providing additional validation and funding.
- The pipeline offers multiple shots on goal across Alzheimer's (AL137, AL064) and Parkinson's (AL050, ADP062-ABC), which bulls view as diversified optionality.
- Biotech valuations can re-rate quickly on positive clinical data or partnership news, and analyst target increases have followed the deal.
What Could Prevent the Target From Being Reached
- The company is loss-making and cash-burning, which can force dilutive financings that pressure the share price.
- Alector has a demonstrated history of trial-driven drawdowns — the AL001 (latozinemab) INFRONT-3 miss in late 2025 triggered sharp price-target cuts across the Street.
- Valuation remains highly binary: without a clinical win, the shares have repeatedly fallen toward the $1 level.
- Analyst opinion is split, with two firms carrying Hold or Sell ratings and targets below the current price, reflecting limited conviction in near-term catalysts.
Technical Levels and Market Structure
The stock's 52-week range of $1.09 to $3.40 frames the relevant technical landscape. The $1.09 low, set in December 2025 after the INFRONT-3 setback, acts as a durable support zone, while the $3.40 high from October 2025 is the key overhead reference. A move toward the $3.60 target would require first reclaiming the $2–$2.50 zone and then clearing the prior $3.40 high — a level the stock has not traded above since 2025. The $1.50–$2.00 band has functioned as a congested trading area for much of 2026.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though the exact horizon varies by firm and is not always disclosed. For Alector, the most relevant catalysts ahead include updates on the AL050 program as it moves toward the clinic under Genentech, any new data or milestones from the GSK collaboration, quarterly earnings and cash-burn disclosures, and any further analyst rating or target revisions following the licensing announcement. Regulatory and partnership milestones are likely to matter more to the share price than near-term financial results. From what I see, this is important because pipeline progress often drives the biggest re-ratings in this space.
AI Daily Buy/Sell Signals
For traders monitoring volatile, news-driven names such as Alector, AI Daily Buy/Sell Signals can help streamline the process. Tickeron's platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the tool to discover new opportunities, track existing positions, and identify shifting trends more efficiently than manual scanning. For investors looking to stay ahead of fast-moving biotech setups, exploring Tickeron's AI Daily Buy/Sell Signals is a practical next step.
Final Assessment
The question of whether Alector can reach $3.60 is best understood as a question about execution rather than valuation. The $3.60 figure is the arithmetic mean of four explicit analyst targets spanning $1.50 to $6.00 — a range so wide that the midpoint should not be mistaken for a confident forecast. From the last close of $1.81, the required move of roughly 99% is very large, and it would almost certainly depend on the AL050 program advancing successfully under Genentech and on renewed clinical momentum elsewhere in the pipeline. The new partnership strengthens the balance sheet and validates a key asset, but the company remains loss-making, and its recent history of trial-driven sell-offs is a genuine obstacle. Investors should watch pipeline and partnership milestones, cash runway, and analyst revisions rather than any single price level. I’m watching this closely as the partnership news could shift sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ALEC sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for ALEC moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +4.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 219 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 158 of 184 cases where ALEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALEC moved out of overbought territory on September 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 14 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALEC as a result. In 86 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for ALEC turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 35 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ALEC moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALEC crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
ALEC broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.924) is normal, around the industry mean (26.780). P/E Ratio (14.327) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ALEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders
Industry Biotechnology
Advertisement